Session » Osteoarthritis & Joint Biology – Basic Science Poster

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1968

A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1992

Adenosine A2A Receptor (A2AR) Stimulation Mitigates Mitochondrial Inflammaging, Enhances Mitochondrial Metabolism and Reduces Reactive Oxygen Species-Mediated Mitochondrial Injury In Vitro and In Vivo in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1967

Adenosine A2A Receptor Signals Through AMPK and SIRT1 to Increase Chondrocyte Homeostasis

9:00AM-11:00AM: Abstract Number: 1984

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model but Not in A2A KO Mice

9:00AM-11:00AM: Abstract Number: 1987

CCN3 Regulates Macrophage Function in MSU-induced Inflammation

9:00AM-11:00AM: Abstract Number: 1971

CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis

9:00AM-11:00AM: Abstract Number: 1980

Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice

9:00AM-11:00AM: Abstract Number: 1985

Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1988

Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSc) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk

9:00AM-11:00AM: Abstract Number: 1975

Fibrates as Drugs with Senolytic and Autophagic Activity for Osteoarthritis Treatment

9:00AM-11:00AM: Abstract Number: 1969

FOXO1 Is Required for Human Osteoclast Differentiation

9:00AM-11:00AM: Abstract Number: 1981

Functional Differences Between Osteoclasts and Osteoclast-like Cells Differentiated from Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1978

HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1972

Identification of Distinct Lipidomic Profiles in Synovial Membranes from Inflammatory Arthritis by Mass Spectrometry Imaging

9:00AM-11:00AM: Abstract Number: 1991

Inhibition of CD44 Intracellular Domain Production Suppresses Bovine Articular Chondrocyte De-differentiation Induced by Excessive Mechanical Stress Loading

9:00AM-11:00AM: Abstract Number: 1993

Inhibition of Choline Kinase Alpha Improves Synovitis and Cartilage Damage in Animal Models of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1986

Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles

9:00AM-11:00AM: Abstract Number: 1970

Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose

9:00AM-11:00AM: Abstract Number: 1989

Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal

9:00AM-11:00AM: Abstract Number: 1983

Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1973

Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies

9:00AM-11:00AM: Abstract Number: 1976

Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5

9:00AM-11:00AM: Abstract Number: 1982

Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain

9:00AM-11:00AM: Abstract Number: 1990

Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor

9:00AM-11:00AM: Abstract Number: 1974

The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection

9:00AM-11:00AM: Abstract Number: 1977

The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment

9:00AM-11:00AM: Abstract Number: 1979

What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].